D. A. Gagloeva

D. A. Gagloeva

Auto-generated profile, based on publicly available information

D. A. Gagloeva

Chazov National Medical Research Center of Cardiology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
DGD.A. Gagloeva
D.A. Gagloeva
NMN.YU. Mironov
N.YU. Mironov
LLL.YU. Lajovich
L.YU. Lajovich
NMN.A. Mironova
N.A. Mironova
SGS.P. Golitsyn
S.P. Golitsyn
Фибрилляция предсердий (ФП) является самым частым нарушением ритма сердца у больных хронической сердечной недостаточностью (ХСН). Патологические процессы, протекающие у больных ХСН, создают условия для возникновения ФП, которая способствует дальнейшему усугублению состояния пациентов. Лечение больных ФП и ХСН представляется сложной задачей, поскольку оба этих патологических процесса оказывают негативное влияние на тяжесть состояния пациента. Кроме того, у этих больных имеются существенные ограничения в возможности использования медикаментозной терапии и зачастую возникает потребность в применении интервенционных методов лечения. В данном обзоре рассмотрены патофизиологические механизмы развития ХСН при ФП, варианты клинического течения заболевания, а также обобщены существующие в настоящее время различные тактики ведения данной категории больных.

8 May 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
DGD. A. Gagloeva
D. A. Gagloeva
KDKh. M. Dzaurova
Kh. M. Dzaurova
МЗМ. А. Зельберг
М. А. Зельберг
NMN. Yu. Mironov
N. Yu. Mironov
YYYu. A. Yuricheva
Yu. A. Yuricheva
ЮЮЮ. А. Юричева
Ю. А. Юричева
Aim. To compare the efficacy and safety of chemical cardioversion (CCV) with refralon and amiodarone in patients with paroxysmal atrial fibril­lation and flutter (AF/AFL).Material and methods. Fifty five patients (mean age, 65±11 years) with paroxysmal AF/AFL were included. All patients underwent a preliminary examination to rule out contraindications to CCV. Further, patients were randomized into groups of refralon (n=30) and amiodarone (n=28), respectively. CCV with refralon was carried out as follows: administration in doses of 5-5-10-10 µg/kg at intervals of 15 minutes. Patients of the second group were intravenously injected with amiodarone at a dose of 5 mg/kg of body weight for 20-60 minutes, depending on the drug tolerability. If AF/AFL persists after 60 minutes, infusion of amio­darone 100 mg/hour until restoration of sinus rhythm (SR) or reaching a dose of 1200 mg/day. Treatment efficacy was assessed by SR reco­very, absence of AF/AFL recurrence, and arrhythmia relief time, and safety was assessed by detection of ventricular arrhythmogenic effects, bradyarrhythmias, blood pressure reduction, and QT interval prolongation. The follow-up period lasted 24 hours.Results. SR was restored in 96,7% (n=29) of patients in the refralon group, of which 56,7% (n=17) after a dose of 5 mcg/kg. In the amio­darone group, SR was restored in 57,1% (n=16) of patients (p<0,001). The arrhythmia relief time in the refralon group was 14 [7;23] min, while in the amiodarone group — 150 [82;240] min (p<0,001). There were no significant differences in the incidence of bradyarrhythmias, lowering blood pressure, and QT prolongation in the groups.Conclusion. Refralon demonstrates a higher efficiency and lower time to AF/AFL relief compared with amiodarone, while in most patients, SR recovery occurs after the administration of the lowest doses, which ensures CCV safety.

25 September 2025 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
SGS. P. Golitsyn
S. P. Golitsyn
EPElizaveta Panchenko
Elizaveta Panchenko
NMN. Yu. Mironov
N. Yu. Mironov
MBMaria Beliaeva
Maria Beliaeva
DGD. A. Gagloeva
D. A. Gagloeva
OSO. O. Shakhmatova
O. O. Shakhmatova
In this document we provide comprehensive review of contemporary approaches to diagnostic work-up and management of atrial fibrillation (AF) in adults. These guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. Previous version of Eurasian clinical practice guidelines published in 2019 required revision due to a number of randomized clinical trials in major medical and surgical approaches to AF published in 2019-2024. Updated version of Eurasian Clinical practice guidelines based on methodology of European society of cardiology guidelines (2024) and American heart association/ American College of cardiology guidelines (2023). Revision included not only new scientific data but also took into consideration regional differences in healthcare systems, medical services and drugs availability and epidemiology of AF in Eurasian region.

30 June 2023 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
DGD. A. Gagloeva
D. A. Gagloeva
KDKh. M. Dzaurova
Kh. M. Dzaurova
MZM. A. Zelberg
M. A. Zelberg
NMN. Yu. Mironov
N. Yu. Mironov
YYYu. A. Yuricheva
Yu. A. Yuricheva
SGS. P. Golitsyn
S. P. Golitsyn
Aim      Evaluating the efficacy and safety of early administration of antirecurrence antiarrhythmic therapy (AAT) following restoration of sinus rhythm (SR) with refralon. Aim      Evaluating the efficacy and safety of early administration of antirecurrence antiarrhythmic therapy (AAT) following restoration of sinus rhythm (SR) with refralon. Material and methods  The study included 247 patients with atrial fibrillation/atrial flutter (AF/AFL) (142 men) who underwent pharmacological cardioversion (PCV) with refralon. A 4-step schedule of drug administration was used (successive intravenous infusions at doses of 5, 5, 10, and 10 µg/kg; maximum total dose was 30 µg/kg). Patients who recovered SR and had no contraindications were prescribed antirecurrence AAT in the early (≤24 h; n=101) or delayed (≥24 h; n=95) period. Lappaconitine hydrobromide, propafenone, and sotalol were administered orally as the antirecurrence therapy. The decision on the time of initiating ATT and the choice of the drug and its dose was taken by the attending physician individually. The safety criteria included a prolonged PQ interval >200 ms; second- or third-degree atrioventricular block; QRS complex duration >120 ms; QT prolongation >500 ms; and heartbeat pauses >3 s. The efficacy criteria included the absence of sustained recurrence of AF/AFL after initiation of AAT and the duration of hospitalization after PCV. Patients were followed up during the study until they were discharged from the hospital. Results SR was recovered in 229 (92.7 %) patients. In the group of early AAT initiation, a PQ duration >200 ms was observed in 8 (7.9 %) patients, whereas in the group of delayed AAT initiation, in 7 patients (7.4 %; p=1.000). A wide QRS complex >120 ms was recorded in 1 (1.1 %) patient of the delayed AAT initiation group and in none of the patients of the early AAT initiation group (p=0.485). Ventricular arrhythmogenic effects and QT prolongation >500 ms were not detected in any patient. Numbers of early AF recurrence did not differ in the groups of early and delayed AAT initiation: 6 (5.9 %) vs . 5 (5.3 %), respectively (p=1.000). Median duration of hospitalization after PCV was 4 days in the group of early AAT initiation and 5 days in the group of delayed AAT initiation (р=0.009). Conclusion      Early initiation of the refralon AAT does not increase the risk of drug adverse effects and reduces the duration of stay in the hospital.

27 May 2024 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
МЗМ. А. Зельберг
М. А. Зельберг
NMN. Yu. Mironov
N. Yu. Mironov
KDKh. M. Dzaurova
Kh. M. Dzaurova
YYYu. A. Yuricheva
Yu. A. Yuricheva
EME. B. Maykov
E. B. Maykov
ЮЮЮ. А. Юричева
Ю. А. Юричева
Objective. Evaluate efficacy and safety of cavutilide (Refralon) for pharmacological cardioversion in patients with recurrent atrial fibrillation and flutter (AF/AFL), in 90days blanking period of catheter ablation.Materials and methods. included 56 patients: 46 patients with recurrent paroxysmal AF/AFL and 10 patients with recurrent persistent AF/AFL. In 45 patients (80.3%), sinus rhythm (SR) restoration was performed within 7 days from the moment of catheter ablation. Intraoperative confirmation of pulmonary vein (PV) isolation was noted in 85.7% cases (n=48). After excluding contraindications, cavutilide was administrated in the intensive care unit according to a 4-stage protocol (5 µg/kg – 5 µg/kg-10 µg/ kg – 10 µg/kg). Effectiveness of pharmacological cardioversion was assessed as the fact of restoring SR and the fact of preservation of SR 24 hours after cavutilide administration. Safety points – QT prolongation, ventricular arrhythmogenic effects, pauses and bradyarrhythmias.Results. The overall effectiveness of cavutilide among all included patients reached 98.2% (n=55), and preservation of SR 24 hours after cavutilide administration was observed in 94.5% (n=53) patients. All the patients with recurrent persistent AF/AFL successfully restored and maintained SR 24 hours after cavutilide administration 100% (n=10). In patients with recurrent paroxysmal AF/AFL restoration of SR observed in 97.8% (n=45) and preservation of SR after 24 hours – in 93.4% (n=43), respectively. The effectiveness of cavutilide did not depend on the results of the catheter ablation. Recurrences of AF/AFL after SR restoration were more common in patients without successful PV isolation. QT prolongation >500ms observed in 8.9% (n=5) of cases, including 1 case of self-terminating torsade de pointes, managed by MgSO4 infusion. Bradyarrhythmias that did not require urgent therapy were noted in 10.7% (n=6) of cases.Conclusion. Pharmacological cardioversion with Cavutilide (Refralon) is highly effective and safe method of SR restoration in patients with recurrent AF/AFL in 90days blanking period after catheter ablation.

22 March 2026 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
DGD. A. Gagloeva
D. A. Gagloeva
EKE. S. Kropacheva
E. S. Kropacheva
NMN. Yu. Mironov
N. Yu. Mironov
SGS. P. Golitsyn
S. P. Golitsyn
In the treatment of patients with atrial fibrillation (AF) and atrial flutter (AFL), the best results are achieved using a comprehensive approach. This facilitates the selection of the optimal management strategy for each individual patient based on current clinical guidelines. Cardioversion is a crucial component of the rhythm control strategy, aimed at both managing symptoms and improving the patient’s prognosis. Selecting the optimal method for restoring sinus rhythm, proper patient preparation, including anticoagulant therapy, and the correct implementation of all procedure stages are essential for achieving an effective and safe outcome. This paper discusses methods for terminating AF and AFL, and provides guidelines for strategies for restoring sinus rhythm and anticoagulant therapy in cardioversion in various clinical situations.